Advertisement

Diabetologia

, Volume 55, Issue 4, pp 877–880 | Cite as

Deploying insulin granule–granule fusion to rescue deficient insulin secretion in diabetes

  • H. Y. GaisanoEmail author
Commentary

Abstract

According to our current understanding of insulin exocytosis, insulin granules dock on the plasma membrane, undergo priming and then wait for calcium-triggered fusion. In this issue of Diabetologia, Hoppa et al (doi  10.1007/s00125-011-2400-5) report that cholinergic stimulation induces granule–granule, or multivesicular, fusion to effect more efficient insulin release. Other exocytotic modes of insulin secretion, particularly those induced by incretin stimulation, include orderly granule fusion with granules already fused with the plasma membrane, called sequential exocytosis, and recruitment of newcomer granules to fuse with plasma membrane with minimal time for docking and priming. The molecular machineries that mediate these distinct exocytotic modes of granule–granule fusion and newcomer granules remain undefined, but they could be therapeutically targeted to couple to cholinergic and incretin stimulation to rescue the deficient glucose-stimulated insulin secretion in diabetes.

Keywords

Cholinergic stimulation Compound exocytosis Glucagon-like peptide 1 Granule–granule fusion Newcomer granules 

Abbreviations

3-D

Three-dimensional

GLP-1

Glucagon-like peptide 1

GSIS

Glucose-stimulated insulin secretion

PKA

Protein kinase A

PKC

Protein kinase C

SNARE

Soluble N-ethylmaleimide-sensitive factor attachment protein receptor

SRB

Sulforhodamine B

STXBP

Syntaxin-binding protein

Insulin granule fusion with the plasma membrane, termed exocytosis, releases insulin into the circulation to maintain glucose homeostasis in health [1]. In diabetes there are well-described defects in insulin exocytosis that prevent the beta cells from responding adequately to the increasing glycaemic demand [2]. Stimulation of insulin secretion can be effected by increasing the number of individual insulin granules reaching (and fusing with) the plasma membrane. This process is called primary exocytosis, and this occurs in two modes (Fig. 1). The first mode involves insulin granule docking on the plasma membrane followed by priming (the biochemical preparation of the granule for release). The granule then sits on the plasma membrane for long periods awaiting glucose stimulation to cause its exocytotic fusion. This is believed to be the primary contributor to first-phase glucose-stimulated insulin secretion (GSIS) [3]. In the second mode of primary exocytosis, insulin granules from the beta cell interior are mobilised to the plasma membrane and undergo fusion after only a short period of, or almost no, docking time, called newcomer granules [3, 4] (Fig. 1). The insulin granules involved in the latter mode of primary exocytosis are termed newcomer granules. These are responsible for the majority of second-phase GSIS and contribute to a substantial proportion of first-phase release [3, 4].
Fig. 1

Modes of insulin granule exocytosis in the pancreatic islet beta cell

There is a third mode of insulin exocytosis, termed compound exocytosis (Fig. 1). This was first shown many years ago by electron microscopy but was largely ignored [5]. More recent work employing two-photon microscopy of extracellular polar dye sulforhodamine B (SRB) have shown compound exocytosis to account for a near-negligible 2–3% of the exocytosis elicited by glucose stimulation [6]. Two-photon microscopy is the method with the highest temporal and spatial resolution for the detection of the permeation of SRB into exocytosing granules as fusion pores open to the cell exterior. However, in the initial elegant studies [5], insulin granules were shown to fuse, with some delay, to granules that had already fused with the plasma membrane, hence this type of compound fusion was termed sequential granule fusion; and this involved only two, or sometimes three, granules [6]. The incretin hormone glucagon-like peptide 1 (GLP-1), which is well known to greatly potentiate GSIS via cAMP and protein kinase A (PKA) pathways and is currently used clinically to treat diabetes, was shown to increase GSIS by increasing primary exocytosis and sequential exocytosis [7, 8]. Another mode of granule–granule fusion is multivesicular exocytosis (also known as true compound exocytosis), whereby granules undergo complete or partial fusion inside the cell (homotypic fusion, Fig. 1) before the complex fuses with the plasma membrane as a single unit [9]. This means that the insulin content of multiple prefused granules could be released simultaneously, effecting more efficient release of insulin than the slower metered release of sequential granule fusion. Multivesicular exocytosis was thought to be a less pronounced mode of exocytosis in beta cells, in contrast to the situation in many secretory cells, such as mast cells [10], eosinophils [11] and neutrophils [12]. In these secretory cells, a very large number of granules undergo rapid homotypic fusion to enable a massive release of granule cargo to effect the desired actions—allergic reactions [10], killing of invading parasites [11] and the acute inflammatory response [12], respectively. Neuroendocrine cells such as beta cells seem to require less of this mode of compound exocytosis and instead exhibit a slower metered and sustained release, primarily effected by increasing primary exocytosis and, when required, release is further increased by restricted sequential fusion of only a few granules of two or three [6, 7]. This metered release is also the mode by which polarised pancreatic acinar cells release digestive enzymes. However, in acinar cells, sequential exocytosis is much more extensive and is the primary mode used to increase secretion [13, 14, 15]. This is because the size of the acinar apical plasma membrane is extremely limited (5% of total plasma membrane surface) and so there is not enough space available for additional primary exocytosis during periods of increased demand [13, 14, 15].

In this issue of Diabetologia, Hoppa et al. [16] report that, contrary to current thinking, multivesicular exocytosis could be upregulated in rat islet beta cells by the muscarinic agonist carbachol, acting primarily by evoking global elevation of cytosolic calcium and, to a lesser degree, protein kinase C (PKC). Compound exocytosis was observed to represent only ~5% of the insulin release events stimulated by 20 mmol/l glucose, but this was increased to 18% in the presence of the cholinergic agonist carbachol, enhancing GSIS by as much as 40%. Compound exocytosis was demonstrated by employing several complementary strategies. Two-photon imaging of SRB showed compound exocytotic events to be fivefold larger than single vesicles, and this observation was corroborated by three-dimensional (3-D) images constructed using confocal imaging (fixable FM1-43 dye) and electron microscopy. Fusion pores between these large numbers of homotypically fused granules remained open for tens of seconds, implying that there was sufficient time for multivesicular insulin cores to empty into the cell exterior. In addition, 3-D electron microscopy revealed that pretreatment with carbachol induced a threefold increase in homotypically fused granules, and occasionally up to six granules were observed to be prefused within the cell prior to fusion with the plasma membrane. Many of these multivesicular structures were located close to (within 1 μm) the plasma membrane in proximity to the primary source of fusogenic calcium arising from influx via plasma membrane calcium channels.

Interestingly, Hoppa et al. did not observe a significant increase in primary exocytosis, shown in other reports to occur in response to GLP-1 potentiation [7, 8]. In addition, granule–granule fusion kinetics varied according to the stimulating compound used, with GLP-1-stimulated release largely the result of sequential fusion [7, 8] and carbachol-stimulated release largely produced by multivesicular fusion [16]. This would suggest that downstream exocytotic fusion molecules acted upon by carbachol-evoked calcium (and PKC) signalling may be distinct from the exocytotic molecules coupled to GLP-1-evoked cAMP/PKA signalling. What are these exocytotic substrates that mediate the distinct exocytotic events, namely, primary exocytosis of docked and newcomer granules, and the granule–granule fusion that underlies sequential and multivesicular exocytosis? While much is known about the molecular machinery that mediates the primary exocytosis of docked insulin granules, namely, the neuronal soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins syntaxin 1A, synaptosomal-associated protein of 25 kDa (SNAP25) and vesicle-associated membrane protein 2 (VAMP2), and SNARE complex assembly-modulating proteins, including the PKC substrate syntaxin-binding protein 1 (STXBP1, also known as MUNC18-1) [17], very little is known about the molecular machinery that mediates the other exocytotic events. Interactions of another member of the STXBP family, STXBP3, with syntaxin 4 have been shown to influence second-phase GSIS, but the precise exocytotic event has not been elucidated [18]. A recent paper on STXBP2 reported that overexpression of this member of the STXBP family in beta cells increased calcium sensitivity to evoke a larger exocytotic response [19], implicating that this protein modulates a distinct set of SNARE proteins. Much further work will be required to elucidate the identities and functions of these as yet undefined membrane fusion SNARE molecules, the accessory proteins that modulate the assembly and disassembly of these SNARE complexes and the precise exocytotic events shown in Fig. 1 that each set of these proteins mediates.

The molecular machineries that mediate granule–granule fusion (sequential and multivesicular) and newcomer granule exocytosis are of importance for increasing insulin secretion in response to the increased demand in diabetes. These are required to compensate for the defective exocytosis of docked granules, which has been shown to account for reduced first-phase GSIS in type 2 diabetes [17, 20] and has been attributed to reduced beta cell levels of the neuronal SNARE complex proteins and STXBP1 [21]. This is also important for type 1 diabetes since, at early stages of the disease, the reduced but viable beta cell mass still contains a sufficient number of beta cells to secrete insulin, but secretion needs to be more efficient. Sequential and multivesicular exocytosis would be preferred over primary exocytosis for more efficient release of insulin in both types of diabetes. Considering only a few per cent of total insulin content of each beta cell is released over several hours during a meal, there is potential for insulin release to be vastly increased. By employing this versatile spectrum of exocytotic modes to effect delivery of metered release of insulin to respond precisely and in tandem to physiological increases in glycaemic demand, this avoids insufficient or excessive insulin release, thus maintaining euglycaemia [22]. Under normal conditions, it seems that the exocytotic machineries for granule–granule fusion and recruitment of newcomer granules were deliberately designed to be inherently inefficient in beta cells compared with those found in some secretory cells (mast cells, eosinophils, neutrophils) but more efficient than those present in other secretory cells (pancreatic acinar cells). However, this inherent exocytotic inefficiency renders beta cells unable to respond to excessive increases in glycaemic demand as diabetes worsens. This presents tremendous therapeutic implications and impetus for much more work to be done to elucidate these intrinsic, but undefined, exocytotic fusion machineries that could be coupled to cholinergic and incretin stimulation, thus enabling a more effective deployment of the more efficient exocytotic modes of compound exocytosis and recruitment of newcomer insulin granules to rescue the deficient glucose-dependent insulin secretion in diabetes [17].

Notes

Acknowledgements

Supported by Canadian Institute for Health Research MOP 86544 and MOP 89889.

Contribution statement

The author was responsible for the design of the manuscript, writing the article and approved the version to be published.

Duality of interest

The author declares there is no duality of interest associated with this manuscript.

References

  1. 1.
    Rorsman P, Renstrom E (2003) Insulin granule dynamics in pancreatic beta cells. Diabetologia 46:1029–1045PubMedCrossRefGoogle Scholar
  2. 2.
    Hosker JP, Rudenski AS, Burnett MA, Matthews DR, Turner RC (1989) Similar reduction of first- and second-phase B cell responses at three different glucose levels in type II diabetes and the effect of gliclazide therapy. Metabolism 38:767–772PubMedCrossRefGoogle Scholar
  3. 3.
    Ohara-Imaizumi M, Fujiwara T, Nakamichi Y et al (2007) Imaging analysis reveals mechanistic differences between first- and second-phase insulin exocytosis. J Cell Biol 177:695–705PubMedCrossRefGoogle Scholar
  4. 4.
    Shibasaki T, Takahashi H, Miki T et al (2007) Essential role of Epac2/Rap1 signaling in regulation of insulin granule dynamics by cAMP. Proc Natl Acad Sci USA 104:19333–19338PubMedCrossRefGoogle Scholar
  5. 5.
    Orci L, Malaisse W (1980) Hypothesis: single and chain release of insulin secretory granules is related to anionic transport at exocytotic sites. Diabetes 29:943–944PubMedGoogle Scholar
  6. 6.
    Takahashi N, Hatakeyama H, Okado H et al (2004) Sequential exocytosis of insulin granules is associated with redistribution of SNAP25. J Cell Biol 165:255–262PubMedCrossRefGoogle Scholar
  7. 7.
    Kwan EP, Gaisano HY (2005) Glucagon-like peptide 1 regulates sequential and compound exocytosis in pancreatic islet beta-cells. Diabetes 54:2734–2743PubMedCrossRefGoogle Scholar
  8. 8.
    Kasai H, Suzuki T, Liu TT, Kishimoto T, Takahashi N (2002) Fast and cAMPsensitive mode of Ca2+-dependent exocytosis in pancreatic beta-cells. Diabetes 51(Suppl 1):S19–S24PubMedCrossRefGoogle Scholar
  9. 9.
    Pickett JA, Edwardson JM (2006) Compound exocytosis: mechanisms and functional significance. Traffic 7:109–116PubMedCrossRefGoogle Scholar
  10. 10.
    Fernandez JM, Neher E, Gomperts BD (1984) Capacitance measurements reveal stepwise fusion events in degranulating mast cells. Nature 312:453–455PubMedCrossRefGoogle Scholar
  11. 11.
    Hafez I, Stolpe A, Lindau M (2003) Compound exocytosis and cumulative fusion in eosinophils. J Biol Chem 278:44921–44928PubMedCrossRefGoogle Scholar
  12. 12.
    Lollike K, Lindau M, Calafat J, Borregaard N (2002) Compound exocytosis of granules in human neutrophils. J Leukoc Biol 71:973–980PubMedGoogle Scholar
  13. 13.
    Nemoto T, Kimura R, Ito K et al (2001) Sequential-replenishment mechanism of exocytosis in pancreatic acini. Nat Cell Biol 3:253–258PubMedCrossRefGoogle Scholar
  14. 14.
    Cosen-Binker L, Binker MG, Wang CC, Hong W, Gaisano HY (2008) VAMP8 is the v-SNARE mediating basolateral exocytosis in alcoholic pancreatitis. J Clin Invest 118:2535–2551PubMedGoogle Scholar
  15. 15.
    Behrendorff N, Dolai S, Hong W, Gaisano HY, Thorn P (2011) Vesicle-associated membrane protein 8 (VAMP8) is a SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) selectively required for sequential granule-to-granule fusion. J Biol Chem 286:29627–29634PubMedCrossRefGoogle Scholar
  16. 16.
    Hoppa MB, Jones E, Karanauskaite J et al (2012) Multivesicular exocytosis in rat pancreatic beta cells. Diabetologia. doi: 10.1007/s00125-011-2400-5
  17. 17.
    Kwan EP, Gaisano HY (2009) Rescuing the subprime meltdown in insulin exocytosis in diabetes. Ann N Y Acad Sci 1152:154–164PubMedCrossRefGoogle Scholar
  18. 18.
    Jewell JL, Oh E, Thurmond DC (2010) Exocytosis mechanisms underlying insulin release and glucose uptake: conserved roles for Munc18c and syntaxin 4. Am J Physiol Regul Integr Comp Physiol 298:R517–R531PubMedCrossRefGoogle Scholar
  19. 19.
    Mandic SA, Skelin M, Johansson JU, Rupnik MS, Berggren PO, Bark C (2011) Munc18-1 and Munc18-2 proteins modulate β-cell Ca2+ sensitivity and kinetics of insulin exocytosis differently. J Biol Chem 286:28026–28040PubMedCrossRefGoogle Scholar
  20. 20.
    Ohara-Imaizumi M, Nishiwaki C, Kikuta T, Nagai S, Nakamichi Y, Nagamatsu S (2004) TIRF imaging of docking and fusion of single insulin granule motion in primary rat pancreatic beta-cells: different behaviour of granule motion between normal and Goto–Kakizaki diabetic rat beta-cells. Biochem J 381:13–18PubMedCrossRefGoogle Scholar
  21. 21.
    Ostenson CG, Gaisano HY, Sheu L, Tibell A, Bartfati T (2006) Impaired gene and protein expression of exocytotic SNARE complex proteins in pancreatic islets of type 2 diabetic patients. Diabetes 55:435–440PubMedCrossRefGoogle Scholar
  22. 22.
    Quintens R, Hendrickx N, Lemaire K, Schuit F (2008) Why expression of some genes is disallowed in beta-cells. Biochem Soc Trans 36:300–305PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  1. 1.Department of MedicineUniversity of TorontoTorontoCanada
  2. 2.Department of PhysiologyUniversity of TorontoTorontoCanada

Personalised recommendations